Atrium Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
RNA Nasdaq 2830 atriumtherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Atrium Therapeutics, Inc.

Here's Why We're Not Too Worried About Atrium Therapeutics' (NASDAQ:RNA) Cash Burn Situation - May 28th, 2026 4:24 am
Atrium Therapeutics Reports First Quarter 2026 Financial Results - May 14th, 2026 2:40 pm
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration - Apr 23rd, 2026 6:00 am
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 20th, 2026 8:46 pm
Novartis to Buy Breast-Cancer Drug From Synnovation for Up to $3 Billion - Mar 20th, 2026 1:41 am
Novartis Uses US Bond Issue To Expand RNA And Peptide Pipeline - Mar 19th, 2026 11:04 am
Novartis acquisition spin-off pioneers RNA therapeutics for the heart - Mar 19th, 2026 2:00 am
Novartis Raises $11 Billion Bond to Fund $12 Billion Avidity Deal - Mar 17th, 2026 6:09 am
Sector Update: Health Care Stocks Advance Late Afternoon - Mar 16th, 2026 1:42 pm
Avidity (RNA) Moves Date for Shareholder Vote on Novartis Merger - Feb 27th, 2026 2:05 pm
European Stocks Mostly Higher in Friday Trading; French GDP Growth Slows, Inflation Rises - Feb 27th, 2026 9:51 am
Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies - Feb 27th, 2026 7:19 am
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy - Feb 27th, 2026 7:00 am
Atrium spins out of Avidity, aiming to target rare heart diseases with RNA - Feb 27th, 2026 5:58 am
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - Feb 26th, 2026 2:02 pm
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders - Feb 23rd, 2026 6:00 am
The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 - Feb 18th, 2026 3:00 pm
Avidity Biosciences Announces Expected Record Date for Spin-Off - Feb 2nd, 2026 7:44 pm
Immunocore (IMCR) Soars 5.9%: Is Further Upside Left in the Stock? - Jan 22nd, 2026 5:10 am
JPM26: Novartis strengthens neuroscience portfolio with bolt-on deals - Jan 13th, 2026 9:43 am